Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;122(2):217-223.
doi: 10.1007/s12185-025-03966-6. Epub 2025 Mar 9.

Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma

Shuku Sato  1 , Emi Sawazaki  2 , Shun Tsunoda  2 , Wataru Kamata  2 , Tomiteru Togano  2 , Yotaro Tamai  2   3
Affiliations

Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma

Shuku Sato et al. Int J Hematol. 2025 Aug.

Abstract

Background: The prognostic significance of minimal residual disease (MRD) negativity in multiple myeloma (MM) is well-established, and MRD negativity serves as a surrogate marker for treatment outcomes. However, in various clinical trials, achieving MRD negativity often leads to treatment continuation until disease progression. In real-world clinical practice, discontinuing treatment could lower healthcare costs and reduce adverse events.

Methods: We retrospectively analyzed patients who reached MRD negativity and discontinued treatment.

Results: A total of 39 multiple MM cases were included (17 eligible and 22 ineligible for autologous stem cell transplantation). The median time to next treatment was 42.4 months. Ten patients (25%) required additional treatment due to paraproteins or clinical relapse. Cumulative incidence of relapse at 12 and 48 months was 11.7% (95% confidence interval [CI], 4.5-28.2%) and 26.4% (95% CI, 12.8-49.6%), respectively. Multivariate analysis revealed that elevated lactate dehydrogenase (LDH) at first visit and t(4;14) were the only baseline factors significantly associated with worse outcomes. Eight patients (20%) with International Staging System (ISS) = I and with no risk factors (history of extramural disease, elevated LDH, high-risk cytogenetics) had no recurrence.

Conclusion: Although treatment discontinuation in high-risk cases is potentially unsafe, low-risk cases demonstrate potential for treatment-free remission.

Keywords: Multiple myeloma; Treatment-free interval.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing financial interests.

References

    1. Offidani M, Corvatta L, Morè S, Olivieri A. Novel experimental drugs for treatment of multiple myeloma. J Exp Pharmacol. 2021;13:245–64.
    1. Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8:e422–32.
    1. Martinez-Lopez J, Lopez-Muñoz N, Chari A, Dorado S, Barrio S, Arora S, et al. Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence. Blood Cancer J. 2024;14(1):13.
    1. Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;23(4):5988–99.
    1. Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582–96.

LinkOut - more resources